PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21481526-2	2011	DM1 is an antibody-conjugatable maytansinoid that was developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.	Maytansinoid	32-44	immunoglobulin heavy diversity 1-7	Homo sapiens	0-3	
29214842-1	2018	Trastuzumab emtansine is an antibody-drug conjugate comprised of the anti-HER2 monoclonal antibody trastuzumab linked to DM1 (emtansine), a potent cytotoxic maytansinoid derivative, by a stable linker.	Maytansinoid	157-169	immunoglobulin heavy diversity 1-7	Homo sapiens	121-124	
27174129-10	2016	Furthermore, J2898A-SMCC-DM1 clears slightly faster than J2898A-(CH2)3-DM, suggesting that there is a fraction of maytansinoid loss from the SMCC-DM1 ADC, possibly through a thiol-maleimide dependent mechanism.	Maytansinoid	114-126	immunoglobulin heavy diversity 1-7	Homo sapiens	25-28	
27174129-10	2016	Furthermore, J2898A-SMCC-DM1 clears slightly faster than J2898A-(CH2)3-DM, suggesting that there is a fraction of maytansinoid loss from the SMCC-DM1 ADC, possibly through a thiol-maleimide dependent mechanism.	Maytansinoid	114-126	immunoglobulin heavy diversity 1-7	Homo sapiens	146-149	
27174129-11	2016	Experiments on ex vivo stability confirm that some loss of maytansinoid from Ab-SMCC-DM1 conjugates can occur via thiol elimination, but at a slower rate than the corresponding rate of loss reported for thiol-maleimide links formed at thiols derived by reduction of endogenous cysteine residues in antibodies, consistent with expected differences in thiol-maleimide stability related to thiol pKa.	Maytansinoid	59-71	immunoglobulin heavy diversity 1-7	Homo sapiens	85-88	
25738231-3	2015	We identified DM1-mal-BODIPY as a conjugate with little through-space interaction between the maytansinoid and BODIPY chromophores.	Maytansinoid	94-106	immunoglobulin heavy diversity 1-7	Homo sapiens	14-17	
20421541-1	2010	PURPOSE: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells.	Maytansinoid	113-125	immunoglobulin heavy diversity 1-7	Homo sapiens	21-24	
21391620-1	2011	Antibody-maytansinoid conjugates (AMCs) are targeted chemotherapeutic agents consisting of a potent microtubule-depolymerizing maytansinoid (DM1 or DM4) attached to lysine residues of a monoclonal antibody (mAb) using an uncleavable thioether linker or a stable disulfide linker.	Maytansinoid	9-21	immunoglobulin heavy diversity 1-7	Homo sapiens	141-144	
21391620-6	2011	We found that the uncleavable mAb-SMCC-[(3)H]DM1 conjugate was degraded to a single major maytansinoid metabolite, lysine-SMCC-[(3)H]DM1, that was nearly 50-fold less cytotoxic than maytansine.	Maytansinoid	90-102	immunoglobulin heavy diversity 1-7	Homo sapiens	45-48	
21391620-6	2011	We found that the uncleavable mAb-SMCC-[(3)H]DM1 conjugate was degraded to a single major maytansinoid metabolite, lysine-SMCC-[(3)H]DM1, that was nearly 50-fold less cytotoxic than maytansine.	Maytansinoid	90-102	immunoglobulin heavy diversity 1-7	Homo sapiens	133-136	
21391620-7	2011	The two disulfide-linked conjugates, mAb-SPP-[(3)H]DM1 and mAb-SPDB-[(3)H]DM4, were also found to be catabolized to the analogous lysine-linked maytansinoid metabolites.	Maytansinoid	144-156	immunoglobulin heavy diversity 1-7	Homo sapiens	51-54	
20421541-1	2010	PURPOSE: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells.	Maytansinoid	113-125	immunoglobulin heavy diversity 1-7	Homo sapiens	28-31	
20421541-1	2010	PURPOSE: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells.	Maytansinoid	113-125	immunoglobulin heavy diversity 1-7	Homo sapiens	28-31	
16081651-0	2005	Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.	Maytansinoid	35-47	immunoglobulin heavy diversity 1-7	Homo sapiens	92-95